Advertisement

Hepatitis C drug development at a crossroads

Authors

  • David R. Nelson M.D.

    Corresponding author
    1. Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL
    • Section of Hepatobiliary Diseases, University of Florida, 600 SW Archer Road, PO Box 100214, Gainesville, FL 32610-0214
    Search for more papers by this author
    • fax: 352-392-7393


  • Potential conflict of interest: Dr. Nelson is a consultant and received grants from Roche, Vertex, Human Genome Sciences, Bayer, Merck, and Bristol Myers Squibb.

No abstract is available for this article.

Ancillary